International | Germany
Ad-hoc News
02/21/2013 Ad-hoc: Biotest AG: Biotest increases earnings before taxes by 28%
01/22/2013 Ad-hoc: Biotest AG: Increase in Earnings after Tex for Fiscal Year 2012
12/20/2012 Ad-hoc: Biotest AG: FDA Approves Bivigam TM
05/08/2012 Ad-hoc: Biotest AG: Preliminary investigation by public prosecution - Company rejects suspicions
02/20/2012 Ad-hoc: Biotest AG: Slight increase in sales of 2.3% despite difficult market environment
06/21/2011 Ad-hoc: Biotest AG: Agreement with Abbott
04/28/2011 Ad-hoc: Biotest AG: Ad hoc ANNOUNCEMENT
03/22/2011 Ad-hoc: Biotest AG: Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
02/15/2011 Ad-hoc: Biotest AG: Increase in sales of more than 5%
07/14/2010 Ad-hoc: Biotest AG: Preliminary Results
02/16/2010 Ad-hoc: Biotest AG: Biotest significantly increases sales, EBIT above the high level of last year
10/23/2009 Ad-hoc: Biotest AG: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad
08/12/2009 Ad-hoc: Biotest AG: Ad-hoc RELEASE; Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
05/07/2009 Ad-hoc: Biotest AG: Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility'
02/04/2009 Ad-hoc: Biotest AG: Biotest records significant growth in sales and earnings, Majority shareholder terminates discussion about shares' sale
10/28/2008 Ad-hoc: Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares
07/18/2008 Ad-hoc: Biotest AG: strong first half year, profit target raised
05/27/2008 Ad-hoc: Biotest AG: Forecast for turnover and profit raised
02/22/2008 Ad-hoc: Biotest AG: Biotest marked increase in sales and earnings recorded in 2007
09/21/2007 Ad-hoc: Biotest AG:Biotest successfully concludes 10% capital increase
09/11/2007 Ad-hoc: Biotest AG:Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp.
07/19/2007 Ad-hoc: Biotest AG: Biotest significantly increases sales and earnings target for 2007
02/14/2007 Ad-hoc: Biotest AG: Increase in sales and earnings in financial year 2006 higher than expected
05/03/2006 Ad-hoc: Biotest AG:Biotest and Sanquin plan a strategic alliance in plasma products
10/10/2005 Ad hoc news: Biotest fixes subscription price
09/06/2005 Ad hoc news: Biotest AG increases capital stock by up to EUR 3.9 million
06/30/2005 Ad hoc news: Biotest AG increases capital stock by 2.92 million Euro
03/24/2005 Ad hoc news: Change of the Supervisory Board
03/16/2005 Ad hoc news: Excellent preliminary result: Biotest achieves group profit of EUR 5.0 million in 2004
04/25/2003 Ad hoc news: Biotest: Positive operating profit before special items from core activities
03/11/2003 Ad hoc news: Notice according to §15 WPHG (German Security Trading Act) Biotest AG's year-end result for 2002 depressed by restructuring expenditure despite sales increase
Corporate News
03/25/2013 News: Biotest AG: Biotest increases Profit before Tax by 28%
03/21/2013 News: Biotest AG: Biotest decides to move into biggest Phase IIb trial in company history
02/04/2013 News: Biotest AG: Biotest announces launch of BIVIGAM(TM)in the United States
01/21/2013 News: Biotest AG: Biotest AG with new sales and distribution activities in Russia and Greece
01/16/2013 News: Biotest AG: Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement
01/09/2013 News: Biotest AG: Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floß to the Board of Management
12/20/2012 News: Biotest AG: FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquid
12/13/2012 News: Biotest AG: Biotest with new management team for research and regulatory affairs
12/11/2012 News: Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China
12/06/2012 News: Biotest AG: Biotest starts clinical development programme of human fibrinogen concentrate to treat serious, life-threatening bleeding
11/13/2012 News: Biotest AG: Biotest increases EBT by 26%
10/24/2012 News: Biotest AG: Biotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%)
08/13/2012 News: Biotest AG: Biotest Group with double digit EBIT growth
08/07/2012 News: Biotest AG: Clinical Data on Efficacy and Safety of Bivigam(TM) accepted by FDA. Sales and profit guidance confirmed despite delays in US registration.
07/16/2012 News: Biotest AG: Biotest AG starts combination therapy study with BT-062 in multiple myeloma
05/10/2012 News: Biotest AG: Annual general meeting approves dividend
05/10/2012 News: Biotest AG: Biotest Group reports substantially higher EBIT
04/23/2012 News: Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil
04/11/2012 News: Biotest AG: Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US market
03/22/2012 News: Biotest AG: Biotest reached an all-time high Profit after Tax
03/22/2012 News: Biotest AG: BT-062 demonstrates rapid and complete tumor eradication in preclinical studies
12/12/2011 News: Biotest AG: Clinical development of BT-062 in multiple myeloma expands into combination therapy
11/24/2011 News: Biotest AG: Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis
11/10/2011 News: Biotest AG: Biotest: Significant Increase in Profit after Tax
08/11/2011 News: Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment; continuing difficult Plasma Protein Product Environment
08/01/2011 News: Biotest AG: Sale of Microbiological Monitoring business to Merck KGaA completed
06/22/2011 News: Biotest AG: Pentaglobin(R) shows high binding capacity against the current EHEC strain and its Shiga-like toxin 2
06/21/2011 News: Biotest AG: Abbott and Biotest Announce Global Agreement to Development and Commercialize Novel Antibody for Autoimmune Diseases
05/12/2011 News: Biotest AG: Biotest AG: Annual General Meeting approves dividend increase
05/10/2011 News: Biotest AG: Sales increase in the first quarter
03/22/2011 News: Biotest AG: Biotest: Monoclonal antibody BT-061 in combination with methotrexate demonstrates good efficacy in Rheumatoid Arthritis
03/22/2011 News: Biotest AG: Sales increase despite difficult market environment
01/27/2011 News: Biotest AG: Interim analysis of the Cytotect(R) Phase III trial in congenital cytomegalovirus (CMV) infection shows clear indication of efficacy
01/19/2011 News: Biotest AG: Biotest erwirbt Vertriebsgesellschaft in Brasilien
12/06/2010 News: Biotest AG: Clinical and pre-clinical data emphasise the potential of
11/17/2010 News: Biotest AG: Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours
11/08/2010 News: Biotest AG: Biotest experiences sales growth
11/03/2010 News: Biotest AG: Biotest submits BivigamTM dossier for regulatory approval to US Food and Drug Administration
10/21/2010 News: Biotest AG: Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis
08/12/2010 News: Biotest AG: Positive perspective despite difficult environment
08/11/2010 News: Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial
08/10/2010 News: Biotest AG: Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis
08/10/2010 News: Biotest AG: BT-061 patent protection significantly expanded
07/14/2010 News: Biotest AG: Biotest increases sales despite greater financial pressure
05/11/2010 News: Biotest AG: Biotest shows sales growth in first quarter 2010 despite a difficult environment
05/06/2010 News: Biotest AG: Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share
05/06/2010 News: Biotest AG: Biotest has recorded sales growth in first quarter 2010 despite a difficult environment
03/19/2010 News: Biotest AG: 2009 brings additional growth
03/17/2010 News: Biotest AG: Monoclonal antibody BT-061 shows efficacy in the indication psoriasis
01/06/2010 News: Biotest AG: Sale of Medical Diagnostics business to Bio-Rad completed
12/07/2009 News: Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacy
12/03/2009 News: Biotest AG: European Commission grants approval of Zutectra(R)
11/05/2009 News: Biotest AG: Biotest increases sales and earnings
10/23/2009 News: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Biotest AG:
10/20/2009 News: Biotest AG: Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis
09/30/2009 News: Biotest AG: Clinical development of BT-063 started
09/28/2009 News: Biotest AG: Biotest AG receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for approval of Zutectra across the EU
08/12/2009 News: Biotest AG:Biotest remains successful
07/07/2009 News: Biotest AG: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.
05/15/2009 News: Biotest AG: Successful Start into 2009
05/07/2009 News: Biotest AG: Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share
04/07/2009 News: Biotest AG: Expansion of product offering and capacity
03/11/2009 News: Biotest AG: Successful Financial Year 2008
02/11/2009 News: Biotest AG: Biotest acquires further plasmapheresis centre
01/21/2009 News: Biotest AG: Cooperation secures additional plasma protein capacity
01/12/2009 News: Biotest AG: Expansion of plasma protein product range
12/15/2008 News: Biotest AG: Enhanced property rights for BT-062
12/10/2008 News: Biotest AG: Biotest expands plasma recovery capacities
12/10/2008 News: Biotest AG: European approval for Haemonine®
10/17/2008 News: Biotest AG: Biotest: proceeding successfully
09/22/2008 News: Biotest AG: Biotest: Promising start of clinical trial with BT062
09/08/2008 News: Biotest AG: Biotest: monoclonal antibody BT-061 shows clear indications of efficacy in the treatment of Psoriasis
08/18/2008 News: Biotest AG: Biotest: US approval increases potential of diagnostic business
08/07/2008 News: Biotest AG: Biotest strengthens self-sufficiency in Plasma Proteins
07/29/2008 News: Biotest AG: Biotest awarded patent protection in the USA
05/27/2008 News: Biotest AG: Payout of dividends increased, forecast improved
05/16/2008 News: Biotest AG: Successful start into the Year 2008
05/05/2008 News: Biotest AG: research into additional indications for monoclonal antibody BT-061
04/14/2008 News: Biotest AG: European approvals expand the market potential for plasma proteins
04/07/2008 News: Biotest AG: Biotest: Successful launch of plasma protein business in the USA
03/11/2008 News: Biotest AG: Biotest achieves major milestones in the development of biotherapeutics
02/22/2008 News: Biotest AG: 2007 a very successful year for Biotest
12/05/2007 News: Biotest AG:Biotest successfully completes acquisition of Nabi Biologics assets
11/09/2007 News: Biotest AG: Nabi shareholders approve sale of Biologics Business Unit to Biotest
11/05/2007 News: Biotest AG: Biotest: plasmapheresis centre in Dortmund opens
09/11/2007 News: Biotest AG:Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp.
08/10/2007 News: Biotest AG: Biotest remains on course for growth
08/01/2007 News: Biotest AG:Biotest and Abbott cooperate on a clinical trial for the expansion of the indication of Cytotect®
07/16/2007 News: Biotest AG: New clinical results increase market potential of Cytotect®
06/25/2007 News: Biotest AG: Biotest achieves further milestones in its monoclonal antibody development
06/15/2007 News: Biotest receives go-ahead to export culture media to the USA
05/03/2007 News: Biotest AG: successful start to 2007
03/13/2007 News: Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase
02/14/2007 News: Biotest AG: 2006 financial year considerably better than expected
01/04/2007 News: Biotest AG: Orphan drug status for Cytotect® in the USA
12/21/2006 News: Biotest AG: Major milestones achieved in the development of monoclonal antibodies. – Commencement of clinical development of BT-061.
11/14/2006 News: Biotest AG: Biotest confirms sales and earnings target following good third quarter
11/02/2006 News: Biotest AG:Biotest obtained approval for improved Hepatect® product in six European countries
10/20/2006 News: Biotest AG: New Automated Assays for TANGO® Automated Blood Bank Systems under Food and Drug Administration Review
10/20/2006 News: Biotest AG: Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics
10/20/2006 News: Biotest AG: Biotest announces important Milestone for Full Line of Manual Blood Bank Reagents
10/20/2006 News: Biotest AG: Olympus and Biotest redefine distribution relationship for Tango® systems
09/28/2006 News: Biotest AG: EMEA Committee in favour of Orphan Drug status for Cytotect®
08/14/2006 News: Biotest AG: Continuing growth
07/11/2006 News: Biotest secures exclusive rights to ImmunoGen’s world leading cytotoxic agent technologyest AG:
05/11/2006 News: Biotest AG: Stock option programme fails to achieve required majority
05/11/2006 News: Biotest AG:Good start to 2006 – a year of growth: Group sales up by 21%, overproportional growth recorded in earnings
03/22/2006 News: Biotest AG:“Focused research, global growth”: Biotest increases its market share worldwide and announces ambitious targets for 2006
03/22/2006 News: Biotest AG:Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years
02/17/2006 News: Biotest AG: Successful financial year 2005: Biotest increases sales, doubles the result and reduces financial liabilities
11/14/2005 Press release: Biotest continues excellent business growth in third quarter: Revenue +9%, EBIT +43%
10/31/2005 Press release: Successful capital increase for Biotest
10/18/2005 Press release: Biotest: World’s Largest Trade Conference is Kickoff for TANGO Marketing in the U.S.
10/13/2005 Press release: Biotest: Intratect® approved for nine European countries
10/11/2005 Press release: Biotest AG: Capital increase - Up to EUR 30 million for research and internationalisation
09/29/2005 Press release: Biotest: New study doubles the market potential of Cytotect®
08/05/2005 Press release: Biotest enjoys continued successful business growth - EBIT +27% in first six months 2005
07/28/2005 Press release: Biotest receives approval for TANGO reagents in US
07/01/2005 Press release: Capital increase: 10 million euro in new funds for antibody research
06/29/2005 Press release: Biotest wins TANGO tender
06/28/2005 Press release: Biotest AG and Boehringer Ingelheim Enter Into
05/20/2005 Press release: Biotest AG: Dr. Thorlef Spickschen new Chairman of the Supervisory Board
05/10/2005 Press release: Biotest : Q1 2005 continues positive trend
04/19/2005 Press release: Biotest : Successful fiscal year 2004 and first quarter of 2005
02/17/2005 Press release: Biotest AG and Lonza Enter into Manufacturing Agreement
01/26/2005 Press release: Biotest recorded revenues of EUR 218 million in 2004
01/21/2005 Press release: Biotest AG and AERES Biomedical Successfully Complete Engineering of the Antibody BT-062
11/22/2004 Press release: Biotest increases operating result by 70%
09/30/2004 Press release: STRATEC and BIOTEST conclude agreement on further development of TANGO
09/29/2004 Press release: Biotest launches new antibody product
07/08/2004 Press release: 2004 General Shareholders' Meeting – Biotest shareholders approve extensive capital measures
04/02/2004 Press release: Biotest generates operating profit in 2003
03/10/2004 Press release: Biotest sells its shareholding in SIFIN
02/23/2004 Press release: Biotest and Iranian Darou Pakhsh form joint venture
02/03/2004 Press release: Management changes at Biotest
01/26/2004 Press release: Biotest generates € 222 million turnover in 2003
10/01/2003 Press release: New chairman for the Biotest supervisory board
07/10/2003 Press release: Prof. Schulz appointed as Biotest`s new Chairman
07/01/2003 Press release: Biotest's new preparation against viral infections approved
06/16/2003 Press release: Successful Treatment of SARS Patients with Biotest Drug
06/10/2003 Press release: Biotest sells its shareholding in Envitec
03/05/2003 Press release: Biotest AG continues to market medical products
02/19/2003 Press release: New French transfusion guidelines will drive growth for Biotest's blood grouping analyser
01/29/2003 Press release: Biotest approved for Prime Standard segment
07/09/2002 Press release: Cooperation of Biotest and Olympus in the US and Canadian Market
05/22/2002 Press release: Biotest considers repurchase of shares
04/15/2002 Press release: Biotest AG achieved a 5.6 % growth in sales in 2001 and maintains dividend continuity
02/19/2002 Press release: Biotest announces stock option program
02/12/2002 Press release: Biotest Executive Dr. Reiner retired
01/21/2002 Press release: Biotest fulfills sales target
Ad-hoc News
07/09/2014 Ad-hoc: Biotest AG: Dr. Bernhard Ehmer to become new CEO of Biotest AG
02/20/2014 Ad-hoc: Biotest AG: Biotest increases earnings after taxes by 38.5%
11/12/2013 Ad-hoc: Biotest AG: Managing Board increases guidance 2013
06/10/2013 Ad-hoc: Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share
06/10/2013 Ad-hoc: Biotest AG: Biotest AG has resolved to utilise its authorised capital with subscription rights for existing shareholders
05/08/2013 Ad-hoc: Biotest AG: Biotest AG plans a capital increase and rights issue
02/21/2013 Ad-hoc: Biotest AG: Biotest increases earnings before taxes by 28%
01/22/2013 Ad-hoc: Biotest AG: Increase in Earnings after Tex for Fiscal Year 2012
12/20/2012 Ad-hoc: Biotest AG: FDA Approves Bivigam TM
05/08/2012 Ad-hoc: Biotest AG: Preliminary investigation by public prosecution - Company rejects suspicions
02/20/2012 Ad-hoc: Biotest AG: Slight increase in sales of 2.3% despite difficult market environment
06/21/2011 Ad-hoc: Biotest AG: Agreement with Abbott
04/28/2011 Ad-hoc: Biotest AG: Ad hoc ANNOUNCEMENT
03/22/2011 Ad-hoc: Biotest AG: Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
02/15/2011 Ad-hoc: Biotest AG: Increase in sales of more than 5%
07/14/2010 Ad-hoc: Biotest AG: Preliminary Results
02/16/2010 Ad-hoc: Biotest AG: Biotest significantly increases sales, EBIT above the high level of last year
10/23/2009 Ad-hoc: Biotest AG: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad
08/12/2009 Ad-hoc: Biotest AG: Ad-hoc RELEASE; Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
05/07/2009 Ad-hoc: Biotest AG: Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility'
02/04/2009 Ad-hoc: Biotest AG: Biotest records significant growth in sales and earnings, Majority shareholder terminates discussion about shares' sale
10/28/2008 Ad-hoc: Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares
07/18/2008 Ad-hoc: Biotest AG: strong first half year, profit target raised
05/27/2008 Ad-hoc: Biotest AG: Forecast for turnover and profit raised
02/22/2008 Ad-hoc: Biotest AG: Biotest marked increase in sales and earnings recorded in 2007
09/21/2007 Ad-hoc: Biotest AG:Biotest successfully concludes 10% capital increase
09/11/2007 Ad-hoc: Biotest AG:Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp.
07/19/2007 Ad-hoc: Biotest AG: Biotest significantly increases sales and earnings target for 2007
02/14/2007 Ad-hoc: Biotest AG: Increase in sales and earnings in financial year 2006 higher than expected
05/03/2006 Ad-hoc: Biotest AG:Biotest and Sanquin plan a strategic alliance in plasma products
10/10/2005 Ad hoc news: Biotest fixes subscription price
09/06/2005 Ad hoc news: Biotest AG increases capital stock by up to EUR 3.9 million
06/30/2005 Ad hoc news: Biotest AG increases capital stock by 2.92 million Euro
03/24/2005 Ad hoc news: Change of the Supervisory Board
03/16/2005 Ad hoc news: Excellent preliminary result: Biotest achieves group profit of EUR 5.0 million in 2004
04/25/2003 Ad hoc news: Biotest: Positive operating profit before special items from core activities
03/11/2003 Ad hoc news: Notice according to §15 WPHG (German Security Trading Act) Biotest AG's year-end result for 2002 depressed by restructuring expenditure despite sales increase
Corporate News
05/07/2014 News: Biotest AG: : Annual general meeting approves again increase of dividend
05/07/2014 News: Biotest AG: Biotest continues to show a sales increase
03/27/2014 News: Biotest AG: Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors
03/25/2014 News: Biotest AG: Biotest increases profit after tax by 38.5 %
02/20/2014 Press release: Information Background on Bivigam 100ml/ 10g voluntary recall
12/20/2013 News: Biotest AG: Biotest receives marketing authorisation for Albiomin(R) in Brazil and approval for commissioning of expanded albumin production
12/10/2013 News: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone
12/03/2013 News: Biotest AG: Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A
11/20/2013 News: Biotest AG: Biotest Pharmaceuticals Honoured with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for 'Business Expansion'
11/12/2013 News: Biotest AG: Biotest increases guidance significanty
10/28/2013 News: Biotest AG: Biotest presents the results of a Phase II study of tregalizumab (BT-061) at the American College of Rheumatology (ACR) Annual Meeting in San Diego
10/24/2013 News: Biotest AG: Biotest AG successfully placed a Schuldschein of EUR 210 m.
10/15/2013 News: Biotest AG: Biotest supports the 'Project Recovery' in turning unused blood products from Canadian blood donations into hemophilia medicine for developing countries
10/11/2013 News: Biotest AG: Biotest AG opens three further plasmapheresis centers in Hungary and the USA
08/13/2013 News: Biotest AG: Biotest increases earnings after tax by 55%
08/05/2013 News: Biotest AG: First patient treated with CivacirTM after Hepatitis C induced liver transplantation in Biotest's Phase III clinical trial
06/26/2013 News: Biotest AG: Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million
05/08/2013 News: Biotest AG: Biotest AG: Annual general meeting approves increase of dividend
05/08/2013 News: Biotest AG: Biotest Group reports increase of EBIT
03/25/2013 News: Biotest AG: Biotest increases Profit before Tax by 28%
03/21/2013 News: Biotest AG: Biotest decides to move into biggest Phase IIb trial in company history
02/04/2013 News: Biotest AG: Biotest announces launch of BIVIGAM(TM)in the United States
01/21/2013 News: Biotest AG: Biotest AG with new sales and distribution activities in Russia and Greece
01/16/2013 News: Biotest AG: Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement
01/09/2013 News: Biotest AG: Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floß to the Board of Management
12/20/2012 News: Biotest AG: FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquid
12/13/2012 News: Biotest AG: Biotest with new management team for research and regulatory affairs
12/11/2012 News: Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China
12/06/2012 News: Biotest AG: Biotest starts clinical development programme of human fibrinogen concentrate to treat serious, life-threatening bleeding
11/13/2012 News: Biotest AG: Biotest increases EBT by 26%
10/24/2012 News: Biotest AG: Biotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%)
08/13/2012 News: Biotest AG: Biotest Group with double digit EBIT growth
08/07/2012 News: Biotest AG: Clinical Data on Efficacy and Safety of Bivigam(TM) accepted by FDA. Sales and profit guidance confirmed despite delays in US registration.
07/16/2012 News: Biotest AG: Biotest AG starts combination therapy study with BT-062 in multiple myeloma
05/10/2012 News: Biotest AG: Annual general meeting approves dividend
05/10/2012 News: Biotest AG: Biotest Group reports substantially higher EBIT
04/23/2012 News: Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil
04/11/2012 News: Biotest AG: Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US market
03/22/2012 News: Biotest AG: Biotest reached an all-time high Profit after Tax
03/22/2012 News: Biotest AG: BT-062 demonstrates rapid and complete tumor eradication in preclinical studies
12/12/2011 News: Biotest AG: Clinical development of BT-062 in multiple myeloma expands into combination therapy
11/24/2011 News: Biotest AG: Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis
11/10/2011 News: Biotest AG: Biotest: Significant Increase in Profit after Tax
08/11/2011 News: Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment; continuing difficult Plasma Protein Product Environment
08/01/2011 News: Biotest AG: Sale of Microbiological Monitoring business to Merck KGaA completed
06/22/2011 News: Biotest AG: Pentaglobin(R) shows high binding capacity against the current EHEC strain and its Shiga-like toxin 2
06/21/2011 News: Biotest AG: Abbott and Biotest Announce Global Agreement to Development and Commercialize Novel Antibody for Autoimmune Diseases
05/12/2011 News: Biotest AG: Biotest AG: Annual General Meeting approves dividend increase
05/10/2011 News: Biotest AG: Sales increase in the first quarter
03/22/2011 News: Biotest AG: Biotest: Monoclonal antibody BT-061 in combination with methotrexate demonstrates good efficacy in Rheumatoid Arthritis
03/22/2011 News: Biotest AG: Sales increase despite difficult market environment
01/27/2011 News: Biotest AG: Interim analysis of the Cytotect(R) Phase III trial in congenital cytomegalovirus (CMV) infection shows clear indication of efficacy
01/19/2011 News: Biotest AG: Biotest erwirbt Vertriebsgesellschaft in Brasilien
12/06/2010 News: Biotest AG: Clinical and pre-clinical data emphasise the potential of
11/17/2010 News: Biotest AG: Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours
11/08/2010 News: Biotest AG: Biotest experiences sales growth
11/03/2010 News: Biotest AG: Biotest submits BivigamTM dossier for regulatory approval to US Food and Drug Administration
10/21/2010 News: Biotest AG: Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis
08/12/2010 News: Biotest AG: Positive perspective despite difficult environment
08/11/2010 News: Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial
08/10/2010 News: Biotest AG: Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis
08/10/2010 News: Biotest AG: BT-061 patent protection significantly expanded
07/14/2010 News: Biotest AG: Biotest increases sales despite greater financial pressure
05/11/2010 News: Biotest AG: Biotest shows sales growth in first quarter 2010 despite a difficult environment
05/06/2010 News: Biotest AG: Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share
05/06/2010 News: Biotest AG: Biotest has recorded sales growth in first quarter 2010 despite a difficult environment
03/19/2010 News: Biotest AG: 2009 brings additional growth
03/17/2010 News: Biotest AG: Monoclonal antibody BT-061 shows efficacy in the indication psoriasis
01/06/2010 News: Biotest AG: Sale of Medical Diagnostics business to Bio-Rad completed
12/07/2009 News: Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacy
12/03/2009 News: Biotest AG: European Commission grants approval of Zutectra(R)
11/05/2009 News: Biotest AG: Biotest increases sales and earnings
10/23/2009 News: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Biotest AG:
10/20/2009 News: Biotest AG: Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis
09/30/2009 News: Biotest AG: Clinical development of BT-063 started
09/28/2009 News: Biotest AG: Biotest AG receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for approval of Zutectra across the EU
08/12/2009 News: Biotest AG:Biotest remains successful
07/07/2009 News: Biotest AG: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.
05/15/2009 News: Biotest AG: Successful Start into 2009
05/07/2009 News: Biotest AG: Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share
04/07/2009 News: Biotest AG: Expansion of product offering and capacity
03/11/2009 News: Biotest AG: Successful Financial Year 2008
02/11/2009 News: Biotest AG: Biotest acquires further plasmapheresis centre
01/21/2009 News: Biotest AG: Cooperation secures additional plasma protein capacity
01/12/2009 News: Biotest AG: Expansion of plasma protein product range
12/15/2008 News: Biotest AG: Enhanced property rights for BT-062
12/10/2008 News: Biotest AG: Biotest expands plasma recovery capacities
12/10/2008 News: Biotest AG: European approval for Haemonine®
10/17/2008 News: Biotest AG: Biotest: proceeding successfully
09/22/2008 News: Biotest AG: Biotest: Promising start of clinical trial with BT062
09/08/2008 News: Biotest AG: Biotest: monoclonal antibody BT-061 shows clear indications of efficacy in the treatment of Psoriasis
08/18/2008 News: Biotest AG: Biotest: US approval increases potential of diagnostic business
08/07/2008 News: Biotest AG: Biotest strengthens self-sufficiency in Plasma Proteins
07/29/2008 News: Biotest AG: Biotest awarded patent protection in the USA
05/27/2008 News: Biotest AG: Payout of dividends increased, forecast improved
05/16/2008 News: Biotest AG: Successful start into the Year 2008
05/05/2008 News: Biotest AG: research into additional indications for monoclonal antibody BT-061
04/14/2008 News: Biotest AG: European approvals expand the market potential for plasma proteins
04/07/2008 News: Biotest AG: Biotest: Successful launch of plasma protein business in the USA
03/11/2008 News: Biotest AG: Biotest achieves major milestones in the development of biotherapeutics
02/22/2008 News: Biotest AG: 2007 a very successful year for Biotest
12/05/2007 News: Biotest AG:Biotest successfully completes acquisition of Nabi Biologics assets
11/09/2007 News: Biotest AG: Nabi shareholders approve sale of Biologics Business Unit to Biotest
11/05/2007 News: Biotest AG: Biotest: plasmapheresis centre in Dortmund opens
09/11/2007 News: Biotest AG:Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp.
08/10/2007 News: Biotest AG: Biotest remains on course for growth
08/01/2007 News: Biotest AG:Biotest and Abbott cooperate on a clinical trial for the expansion of the indication of Cytotect®
07/16/2007 News: Biotest AG: New clinical results increase market potential of Cytotect®
06/25/2007 News: Biotest AG: Biotest achieves further milestones in its monoclonal antibody development
06/15/2007 News: Biotest receives go-ahead to export culture media to the USA
05/03/2007 News: Biotest AG: successful start to 2007
03/13/2007 News: Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase
02/14/2007 News: Biotest AG: 2006 financial year considerably better than expected
01/04/2007 News: Biotest AG: Orphan drug status for Cytotect® in the USA
12/21/2006 News: Biotest AG: Major milestones achieved in the development of monoclonal antibodies. – Commencement of clinical development of BT-061.
11/14/2006 News: Biotest AG: Biotest confirms sales and earnings target following good third quarter
11/02/2006 News: Biotest AG:Biotest obtained approval for improved Hepatect® product in six European countries
10/20/2006 News: Biotest AG: New Automated Assays for TANGO® Automated Blood Bank Systems under Food and Drug Administration Review
10/20/2006 News: Biotest AG: Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics
10/20/2006 News: Biotest AG: Biotest announces important Milestone for Full Line of Manual Blood Bank Reagents
10/20/2006 News: Biotest AG: Olympus and Biotest redefine distribution relationship for Tango® systems
09/28/2006 News: Biotest AG: EMEA Committee in favour of Orphan Drug status for Cytotect®
08/14/2006 News: Biotest AG: Continuing growth
07/11/2006 News: Biotest secures exclusive rights to ImmunoGen’s world leading cytotoxic agent technologyest AG:
05/11/2006 News: Biotest AG: Stock option programme fails to achieve required majority
05/11/2006 News: Biotest AG:Good start to 2006 – a year of growth: Group sales up by 21%, overproportional growth recorded in earnings
03/22/2006 News: Biotest AG:“Focused research, global growth”: Biotest increases its market share worldwide and announces ambitious targets for 2006
03/22/2006 News: Biotest AG:Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years
02/17/2006 News: Biotest AG: Successful financial year 2005: Biotest increases sales, doubles the result and reduces financial liabilities
11/14/2005 Press release: Biotest continues excellent business growth in third quarter: Revenue +9%, EBIT +43%
10/31/2005 Press release: Successful capital increase for Biotest
10/18/2005 Press release: Biotest: World’s Largest Trade Conference is Kickoff for TANGO Marketing in the U.S.
10/13/2005 Press release: Biotest: Intratect® approved for nine European countries
10/11/2005 Press release: Biotest AG: Capital increase - Up to EUR 30 million for research and internationalisation
09/29/2005 Press release: Biotest: New study doubles the market potential of Cytotect®
08/05/2005 Press release: Biotest enjoys continued successful business growth - EBIT +27% in first six months 2005
07/28/2005 Press release: Biotest receives approval for TANGO reagents in US
07/01/2005 Press release: Capital increase: 10 million euro in new funds for antibody research
06/29/2005 Press release: Biotest wins TANGO tender
06/28/2005 Press release: Biotest AG and Boehringer Ingelheim Enter Into
05/20/2005 Press release: Biotest AG: Dr. Thorlef Spickschen new Chairman of the Supervisory Board
05/10/2005 Press release: Biotest : Q1 2005 continues positive trend
04/19/2005 Press release: Biotest : Successful fiscal year 2004 and first quarter of 2005
02/17/2005 Press release: Biotest AG and Lonza Enter into Manufacturing Agreement
01/26/2005 Press release: Biotest recorded revenues of EUR 218 million in 2004
01/21/2005 Press release: Biotest AG and AERES Biomedical Successfully Complete Engineering of the Antibody BT-062
11/22/2004 Press release: Biotest increases operating result by 70%
09/30/2004 Press release: STRATEC and BIOTEST conclude agreement on further development of TANGO
09/29/2004 Press release: Biotest launches new antibody product
07/08/2004 Press release: 2004 General Shareholders' Meeting – Biotest shareholders approve extensive capital measures
04/02/2004 Press release: Biotest generates operating profit in 2003
03/10/2004 Press release: Biotest sells its shareholding in SIFIN
02/23/2004 Press release: Biotest and Iranian Darou Pakhsh form joint venture
02/03/2004 Press release: Management changes at Biotest
01/26/2004 Press release: Biotest generates € 222 million turnover in 2003
10/01/2003 Press release: New chairman for the Biotest supervisory board
07/10/2003 Press release: Prof. Schulz appointed as Biotest`s new Chairman
07/01/2003 Press release: Biotest's new preparation against viral infections approved
06/16/2003 Press release: Successful Treatment of SARS Patients with Biotest Drug
06/10/2003 Press release: Biotest sells its shareholding in Envitec
03/05/2003 Press release: Biotest AG continues to market medical products
02/19/2003 Press release: New French transfusion guidelines will drive growth for Biotest's blood grouping analyser
01/29/2003 Press release: Biotest approved for Prime Standard segment
07/09/2002 Press release: Cooperation of Biotest and Olympus in the US and Canadian Market
05/22/2002 Press release: Biotest considers repurchase of shares
04/15/2002 Press release: Biotest AG achieved a 5.6 % growth in sales in 2001 and maintains dividend continuity
02/19/2002 Press release: Biotest announces stock option program
02/12/2002 Press release: Biotest Executive Dr. Reiner retired
01/21/2002 Press release: Biotest fulfills sales target